Valneva IPO Presentation Deck

Valneva Has Three Highly Differentiated Clinical Programs And Two Commercialised Products Clinical Portfolio Commercial Portfolio Program VLA15¹: Lyme disease VLA1553²: Chikungunya VLA2001: COVID-19 IXIARO: Japanese Encephalitis DUKORAL: Cholera, ETEC³ Discovery Pre-Clinical Phase 1 Valneva - Roadshow Presentation Phase 2 Phase 3 Commercial Potentially Eligible for PRV Upcoming Milestones Further Ph 2 Milestones in 2021 Topline Ph 3 Data mid-2021 Ph 3 data Q3/2021 M Development Partners Pfizer UK Vaccines Task Force VLA15 received Fast Track designation from the FDA. ² VLA1553 received Fast Track designation from the FDA, PRIME designation from the European Medicines Agency and is also potentially eligible for a U.S. Priority Review Voucher. Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium Note: We are developing VLA1601, a highly purified inactivated vaccine candidate for Zika Virus and VLA84, a vaccine candidate against Clostridium difficile. Both of these programs are currently on hold. April 2021

View entire presentation